John Poyhonen - Heron Therapeuti Independent Director
| HRTX Stock | USD 2.34 0.02 0.86% |
Director
Mr. John W. Poyhonen is Independent Director of Heron Therapeutics, Inc. Mr. Poyhonen has more than 25 years of experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. From 2014 through its acquisition by Firmenich, Inc. in November 2018, Mr. Poyhonen was the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx, Inc. in 2003 as Vice President and Chief Business Officer was promoted in 2004 to Vice President and Chief Financial and Business Officer was named Senior Vice President, Chief Financial and Business Officer in 2006 was promoted to President and Chief Operating Officer in 2009 and promoted to President and Chief Executive Officer in 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 through its acquisition by AstraZeneca PLC in 2012 since 2014.
| Age | 64 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 4242 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 251 4400 |
| Web | https://www.herontx.com |
Heron Therapeuti Management Efficiency
The company has return on total asset (ROA) of (0.2456) % which means that it has lost $0.2456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.42 in 2024, whereas Return On Tangible Assets are likely to drop (0.52) in 2024. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 35.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.4 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Amy Hanson | LSI Industries | N/A | |
| Robert Steele | LSI Industries | 62 | |
| Wendell Weeks | Merck Company | 59 | |
| Carlos Represas | Merck Company | 72 | |
| Thomas Cech | Merck Company | 72 | |
| Patricia Russo | Merck Company | 68 | |
| John Noseworthy | Merck Company | 66 | |
| Craig Thompson | Merck Company | 64 | |
| John Morgan | LSI Industries | 63 | |
| Paul Rothman | Merck Company | 63 | |
| William Harrison | Merck Company | 70 | |
| Christine Seidman | Merck Company | 68 | |
| Dennis Meyer | LSI Industries | 80 | |
| Kathy Warden | Merck Company | 49 | |
| Mark Serrianne | LSI Industries | 67 | |
| Leslie Brun | Merck Company | 68 | |
| Pamela Craig | Merck Company | 64 | |
| Gary Kreider | LSI Industries | 78 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Mary Coe | Merck Company | 54 | |
| Inge Thulin | Merck Company | 67 | |
Management Performance
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.25 |
Heron Therapeuti Leadership Team
Elected by the shareholders, the Heron Therapeuti's board of directors comprises two types of representatives: Heron Therapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heron. The board's role is to monitor Heron Therapeuti's management team and ensure that shareholders' interests are well served. Heron Therapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heron Therapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Executive Officer | ||
| Paul Blake, Chief Medical Officer | ||
| Stephen Davis, Director | ||
| John Arthur, Vice President - Manufacturing and Supply | ||
| Chris Storgard, Chief Officer | ||
| Sean Ristine, Vice President - Human Resources | ||
| Michael Mathews, Senior Vice President - Pain Franchise | ||
| John Poyhonen, Independent Director | ||
| Thomas Ottoboni, Senior Vice President - Pharmaceutical and Preclinical Research and Development | ||
| Ira Duarte, Executive CFO | ||
| Brian Drazba, CFO, Vice President - Finance | ||
| Ryan Craig, Vice Marketing | ||
| Barry Quart, CEO, Director | ||
| Christopher Storgard, Senior Vice President - Clinical Development | ||
| Craig Collard, CEO Director | ||
| Robert Sullivan, Senior Operations | ||
| Barry PharmD, Chairman CEO | ||
| Lisa Peraza, VP Officer | ||
| Anita Gupta, Senior Vice President - Medical Strategy and Government Affairs | ||
| Kimberly Manhard, Independent Director | ||
| Michael Adam, Senior Vice President - Regulatory Affairs and Quality | ||
| Christian Waage, Director | ||
| Paul Marshall, Sr. VP of Technical Operations | ||
| Craig Johnson, Independent Director | ||
| Esme Smith, Vice President General Counsel, Secretary | ||
| Neil Clendeninn, Senior Vice President and Chief Medical Officer | ||
| David Szekeres, Senior Vice President General Counsel, Business Development, Corporate Secretary | ||
| Robert Rosen, Pres and Director | ||
| Jesse Hollingsworth, Senior Vice President - Oncology Franchise | ||
| Jeff Cohn, Assistant Director | ||
| Jennifer Capuzelo, IR Contact Officer | ||
| Robert Hoffman, CFO, Senior Vice President - Finance, Principal Accounting Officer |
Heron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heron Therapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.87) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 447.98 M | ||||
| Shares Outstanding | 150.33 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 75.81 % | ||||
| Number Of Shares Shorted | 25.43 M | ||||
| Price To Earning | (5.15) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Heron Therapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Heron Therapeuti's short interest history, or implied volatility extrapolated from Heron Therapeuti options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Heron Stock analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Heron Therapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeuti. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.92 | Quarterly Revenue Growth 0.14 | Return On Assets (0.25) | Return On Equity (24.09) |
The market value of Heron Therapeuti is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeuti's value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeuti's market value can be influenced by many factors that don't directly affect Heron Therapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heron Therapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.